Teva Launches First Generic GLP-1 Weight-Loss Drug in the US

Teva Pharmaceuticals has received FDA approval and launched the first generic glucagon-like peptide-1 (GLP-1) receptor agonist indicated for weight loss in the US5123.

The drug is a generic of Saxenda (liraglutide injection), previously developed by Novo Nordisk, and it is intended for adults with obesity or overweight and at least one weight-related comorbidity, as well as adolescents aged 12–17 with obesity and weighing over 60 kg5123.

This launch addresses significant market demand during a period of global GLP-1 shortages1.

Liraglutide works by mimicking natural GLP-1 to stimulate insulin release, suppress appetite, and help lower blood sugar, supporting weight reduction efforts12.

Both branded Saxenda and Teva's generic version are delivered as injections and are to be used with reduced calorie diets and increased physical activity53.

The prescribing information carries a boxed warning for possible thyroid tumors; patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 must not use it2.

Teva's approval marks the first time a generic GLP-1 is available specifically for weight loss in the U.S., potentially increasing accessibility and affordability for patients53.

Saxenda generated annual sales of $165 million as of June 2025, indicating strong market interest in GLP-1 therapies for obesity management53.

Sources:

1. https://www.bioxconomy.com/modalities/teva-wins-fda-approval-for-first-generic-weight-loss-glp-1

2. https://conexiant.com/endocrinology/articles/first-generic-glp1-for-weight-loss-approved/

3. https://www.managedhealthcareexecutive.com/view/teva-launches-first-generic-glp-1-drug-for-obesity

5. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Teva-Announces-FDA-Approval-and-Launch-of-Generic-Saxenda-liraglutide-injection--First-Generic-GLP-1-Indicated-for-Weight-Loss/default.aspx